arrow
M

Mark Knafl

university of texas m d anderson cancer center
H指数:9
被引数:442

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy and toxicity of hypofractionated radiation therapy for patients with hematologic malignancies: A COVID-era ILROG collaborative report

低分割放射疗法对血液系统恶性肿瘤患者的疗效和毒性:COVID时代的ILROG协作报告

2025-10-040
OAAI
Improved overall survival in an anti-PD-L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features: a single arm prospective phase I/II trial

在抗PD-L1治疗的 Newly Diagnosed Glioblastoma 患者队列中,总体生存率的改善与特定的免疫、突变和肠道微生物组特征相关:一项单臂前瞻性I/II期试验

2025-04-270
OA
KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma

通过液体活检检测胰腺导管腺癌的KRAS基因突变

2025-04-170
OA
Cytokine Storms in COVID-19, Hemophagocytic Lymphohistiocytosis, and CAR-T Therapy

COVID-19中的细胞因子风暴、噬血细胞性淋巴组织细胞增生症,以及CAR-T疗法

2025-04-071
OA
KRAS Q61 mutations in patients with gastrointestinal malignancies and association with real-world clinical outcomes
2024-03-220
PRE
Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma
2024-02-0324
OAAI
Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma
2024-01-160
PRE
Biomarker analysis: Multi-omics elucidation of Cohort 1 from a phase II study of a triple combination of Atezolizumab plus cobimetinib plus eribulin in patients with metastatic inflammatory breast cancer
2023-03-012
PRE
Radiation Therapy Can Be Safely Incorporated into Pretransplantation Treatment Regimens for Patients with Multiple Myeloma
2023-01-013
OAAI
Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma

联合PD-L1 (阿特珠单抗) 和VEGF (贝伐单抗) 阻断治疗晚期恶性腹膜间皮瘤的疗效、安全性和生物标志物分析

2021-07-1448
OA